United States-based ANI Pharmaceuticals, Incorporated (Nasdaq:ANIP) has launched its Mexiletine Hydrochloride Capsules USP, 150mg, 200mg and 250mg, it was reported on Tuesday.
The product is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia.
Patrick Walsh, ANI's interim president and CEO, said, 'This is our sixth generic product launch in 2020. The launch represents an important milestone for ANI in the integration of our Oakville, Canada manufacturing site, acquired in August 2018. Mexiletine is the first new ANI product launch from the Oakville site. I congratulate the team in Oakville on achieving this milestone; we look forward to additional ANI product launches from this plant in the future.'
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US